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Abstract 
Background: The present study takes advantage of the beneficial effects of resveratrol as a neuroprotective com-
pound. Resveratrol-loaded solid lipid nanoparticles were functionalized with apolipoprotein E which can be recog-
nized by the LDL receptors overexpressed on the blood–brain barrier.
Results: Transmission electron microscopy images revealed spherical nanoparticles, dynamic light scattering gave a 
Z-average lower than 200 nm, and a zeta potential of around −13 mV and very high resveratrol entrapment efficiency 
(ca. 90 %). In vitro cytotoxic effects were assessed by MTT and LDH assays in hCMEC/D3 cell line and revealed no 
toxicity up to 50 μM over 4 h of incubation. The permeability through hCMEC/D3 monolayers showed a significant 
increase (1.8-fold higher) for resveratrol-loaded solid lipid nanoparticles functionalized with apolipoprotein E when 
compared to non-functionalized ones.
Conclusions: In conclusion, these nanosystems might be a promising strategy for resveratrol delivery into the brain, 
while protecting it from degradation in the blood stream.
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Background
Resveratrol, a stilbene compound catalogued as a poly-
phenol, has attracted remarkable attention [1]. Among 
other sources, resveratrol may be found in high concen-
trations in the grape skins and seeds, mulberries and pea-
nuts [1–3]. Resveratrol can be found as both cis and trans 
isomeric forms, being trans-isomer the most abundant 
and biologically active form [2, 4]. Only trans-isomer had 
been consistently linked to health beneficial effects in 
pharmacological and clinical studies while cis-resveratrol 
had only seen limited success as an antiplatelet agent [5]. 
Trans-resveratrol is an extremely photosensitive com-
pound susceptible to UV-induced isomerization, being 
rapidly converted to the cis-form [1, 4]. This natural 
compound became popular when the consumption of red 
wine was linked with the low incidence of cardiovascular 
diseases, a phenomenon commonly known as the French 
Paradox [6]. Besides cardioprotective effects, resveratrol 
offers a wide variety of health benefits, such as antioxi-
dant, anti-inflammatory, anti-bacterial, anticarcinogenic 
activities and neuroprotective effects. Specially, resvera-
trol seems to be effective in the treatment of neurological 
disorders, such as Alzheimer’s, Parkinson’s and Hunting-
ton’s diseases, brain ischemia, and epilepsy [7–9]. In fact, 
resveratrol increases antioxidant defense and decreases 
pro-inflammatory cytokines helping to maintain cerebral 
homeostasis [1, 10, 11]. However, pharmacokinetic prop-
erties of resveratrol are not so favorable, being the in vivo 
biological effects of resveratrol strongly conditioned 
due to its poor solubility, chemical instability and rapid 
metabolism, which reduce its bioavailability [2, 12–14]. 
As a consequence, the entrance of resveratrol into the 
brain is limited and this work brings a new strategy to 
overcome these constrains by developing nanosystems 
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capable of protecting resveratrol from the extensive deg-
radation and metabolism and enhancing the delivery into 
the brain in an appropriate therapeutic concentration.
Taking into account the high lipophilicity of resvera-
trol, as well as the high encapsulation efficiency in solid 
lipid nanoparticles (SLNs) previously reported [3, 7, 
15, 16], SLNs were the nanodelivery systems chosen 
to encapsulate resveratrol and transport it to the brain. 
These nanoparticles gather the main advantages of the 
most nanocarriers combined with the high stability of the 
formulations and their easy preparation avoiding the use 
of organic solvents [17, 18]. SLNs constitute an attrac-
tive colloidal resveratrol carrier system with potential for 
brain targeting especially when used polysorbate 80 as 
the surfactant in their preparation [19–24].
Therefore, the aim of this work was the development 
of resveratrol-loaded SLNs to overcome the problems 
of low solubility, protecting it from the degradation and, 
at the same time, targeting it to the brain. For this pur-
pose, resveratrol-loaded SLNs were functionalized with 
apolipoprotein E (ApoE) using two different strategies 
previously described in a recent investigation [25]. ApoE-
functionalized SLNs may mimic lipoprotein particles 
that are endocytosed into the blood–brain barrier (BBB) 
endothelium via low-density lipoprotein (LDL) receptors 
and transcytosed to the brain [26].
Results and discussion
Before the functionalization, SLNs with different 
amounts of resveratrol (0, 2, 5, 10, and 15 mg) were pro-
duced and characterized according to their morphology, 
Z-average, PDI, zeta potential, entrapment efficiency, 
stability over time and release profile. This information 
is available in supplementary information. Resveratrol-
loaded SLNs were then functionalized with ApoE, as 
described [25]. The functionalized nanoparticles were 
also completely characterized and compared with non-
functionalized ones. Furthermore, MTT and LDH assays 
were performed in hCMEC/D3 cell line to evaluate the 
effect of resveratrol-loaded SLNs in cell viability and 
cytotoxicity and permeability studies were also con-
ducted in transwell devices using the same cell line.
Morphology
The shape and morphology of resveratrol-loaded SLNs 
were observed by TEM. The images (Fig. 1) reveal that all 
nanoparticles were almost spherical and uniform in shape. 
The addiction of ApoE to the nanoparticles surface did 
not modify its morphology that remained with a spherical 
shape. The images appear to have an unclear background 
probably due to the presence of phosphate buffer salt crys-
tals. The mean diameter does not exceed 200 nm for all for-
mulations, although SLN-Palmitate-ApoE seems to have a 
slightly larger diameter than the others. There was no vis-
ible aggregation between them. TEM images also revealed 
these formulations produced two populations of nanoparti-
cles, the most abundant with a smaller diameter, and other, 
less pronounced, with a larger size not exceeding 200 nm.
Particle size and polydispersity
The characterization of resveratrol-loaded SLNs can be 
seen in Table 1, where Z-average, PDI, zeta potential and 
EE are presented. Regarding the Z-average, all nanoparti-
cles showed an homogenous size distribution with a mean 
diameter of about 155 nm and no statistically significant 
differences between them were observed (P > 0.05), sug-
gesting that resveratrol incorporation does not directly 
influence the nanoparticles size (Additional file  1: Table 
S1). The addition of ApoE on the surface of SLNs led to a 
slight increase in the nanoparticles size but is only statis-
tically significant for the SLN-Palmitate-ApoE (Table  1). 
These results corroborate the results obtained by TEM 
Fig. 1 TEM images of resveratrol-loaded SLNs: a non-functionalized SLNs; b SLN-DSPE-ApoE RSV; c SLN-Palmitate-ApoE RSV
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where it is noted that the Z-average obtained by DLS is 
larger than the real size of the nanoparticles (showed by 
TEM images) once this device measures the hydrody-
namic size that includes the hydration sphere surrounding 
the nanoparticles. As intended, the SLNs produced have 
an average size less than 200 nm, making them ideal for 
a long-circulation time and for an increased contact time 
between the nanoparticles and the BBB, increasing the 
likelihood to be taken up by the brain [21]. In fact SLNs 
with a size between 120 and 200  nm are able to escape 
from reticuloendothelial system (RES) and thus bypass 
liver and spleen filtration [7]. In relation to PDI, the val-
ues obtained were lower than 0.2 for all nanoformulations 
(Table 1), suggesting that the nanoparticles were in a state 
of acceptable monodispersity distribution, with low varia-
bility and no aggregation. It was also performed a stability 
study during 6 months to evaluate the stability of the for-
mulations in the shelf conditions. Regarding the size, only 
small variations occurred over time when increasing the 
amount of resveratrol, refuting the possibility of aggrega-
tion and agglomeration (Additional file 1: Figure S1). For 
functionalized SLNs, Z-average does not change signifi-
cantly over time, indicating that there is no aggregation of 
particles after 6 months of storage (Fig. 2).
Zeta potential
Zeta potential is basically the surface charge of the nano-
particles and can be an indicator of the potential stabil-
ity over time. Nanoparticles have a natural tendency to 
aggregate, although charged nanoparticles, with high 
negative or positive zeta potential, will repeal each other 
overcoming this problem. Therefore, particles can be con-
sidered stably dispersed when the absolute value of zeta 
potential is above 30  mV due to the electrostatic repul-
sion between the particles, while potentials of 5–15 mV 
result in limited flocculation in solution [3]. All formula-
tions presented (Additional file 1: Table S1 and Table 1) 
have a negative average zeta potential between −10 and 
−15 mV, regardless of resveratrol or ApoE incorporation 
on lipid nanoparticles (P  >  0.05). Therefore, it is essen-
tial to perform a stability study to ascertain the formu-
lations stability over time, once the zeta potential is not 
very high and it may lead to the occurrence of some floc-
culation and aggregation between the nanoparticles. The 
zeta potential of the SLNs developed did not significantly 
change over time (Fig. 3 and Additional file 1: Figure S2). 
Therefore, despite the initial zeta potential value is not as 
high as desired, no tendency for zeta potential to change 
was found during storage conditions, indicating that the 
SLNs developed will be stable at least for 6 months.
Resveratrol entrapment efficiency
Resveratrol EE was evaluated to determine the amount 
of encapsulated resveratrol after SLNs synthesis. Lipid 
nanoparticles are known to be suitable systems for drug 
incorporation especially hydrophobic compounds. There-
fore, resveratrol lipophilic nature suggests a preferential 
partition into nanoparticles lipidic matrix. The results for 
each formulation are shown in Table 1 and EE was found 
to be satisfactorily high, with an average around 90  %. 
The values obtained for functionalized SLNs were found 
to be higher than for non-functionalized ones (Table  1) 
and, by increasing resveratrol concentration, a decrease 
in EE is observed as would be expected (Additional file 1: 
Table S1). By this way, it is possible to state that SLNs are 
Table 1 Characterization of resveratrol-loaded SLNs non-functionalized and functionalized with ApoE
All values represent the mean ± standard deviation (n = 3). Results of functionalized SLNs were analyzed and compared with non-functionalized SLNs. (*) denotes 
statistically significant differences (P < 0.05)
Formulation code Z-average (nm) PDI Zeta potential (mV) Entrapment 
efficiency (%)
SLN non-funct RSV 151.5 ± 5.8 0.161 ± 0.065 −12.4 ± 4.6 88.7 ± 4.6
SLN-DSPE-ApoE RSV 167.8 ± 19.9 0.195 ± 0.049 −13.05 ± 4.06 98.0 ± 2.5
SLN-Palmitate-ApoE RSV 217.1 ± 5.8* 0.077 ± 0.030 −13.54 ± 1.60 98.9 ± 0.6
Fig. 2 Effect of time of storage on particle size of resveratrol-loaded 
SLNs non-functionalized and functionalized with ApoE. Z-average 
after 1 week ( ), 1 month ( ), 3 months ( ), 6 months ( ) and 
PDI ( ). All data represent the mean ± SD (n = 3). No statistically 
significant differences have been found (P > 0.05)
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suitable systems for resveratrol incorporation due to the 
high encapsulation efficiency recorded, well above the 
values reported in the literature for this type of nano-
carriers [27]. The EE was also evaluated over time to 
ascertain about the physical stability of the lipid nanopar-
ticles. SLNs are characterized by having a highly organ-
ized matrix that tends to form perfect crystals over time 
which can eventually lead to an expulsion of the drug 
during the storage period. This is the main disadvantage 
of solid lipid nanoparticles. However, the results of the 
EE over time indicate no statistically significant decreases 
in the resveratrol incorporated, after at least 6  months 
(Fig. 4 and Additional file 1: Figure S3). This suggests that 
SLNs retain the encapsulated compound over time pre-
venting the possibility of expulsion of the drug, showing 
once again the great stability of these formulations.
Release studies
The in vitro release profiles of SLNs can be seen in Fig. 5 
and Additional file  1: Figure S4. This study was per-
formed in SBF to simulate the blood stream conditions 
[28, 29] and represented an important tool for quality 
control and for predicting the in vivo kinetics, providing 
an idea of the release profile in the bloodstream. Despite 
its lipophilic nature, resveratrol has three hydroxyl 
groups present in its structure, which can lead to a loca-
tion not only inside the core of the nanoparticles but also 
at the interface near the shell, favoring an initial burst 
release [30, 31]. Indeed, about 5–10 % of the total amount 
of resveratrol was released after only 15 min of incuba-
tion with SBF, probably indicating the release of the 
non-encapsulated compound or the molecules that were 
merely adsorbed on the surface of the nanoparticles. 
Statistical analysis showed no significant effect on the 
release percentages (ca. 20–25  % after 28  h) comparing 
different initial concentrations of resveratrol (Additional 
file  1: Figure S4). However, functionalized SLNs reduce 
the release profile of the compound (ca. 15 % after 28 h) 
and the initial burst release was not as evident as it was 
on non-functionalized SLNs. Moreover, it was registered 
a more controlled release, almost linear, for both types 
of functionalized SLNs. In fact, the functioning materi-
als, namely the palmitic acid or the phospholipid DSPE, 
in the SLNs matrix reduce the release of the compound 
over time, thereby promoting some kind of interaction 
and stabilization of resveratrol inside the NPs. At the 
same time, the addition of new groups on the surface of 
the nanoparticles creates per se a steric hindrance avoid-
ing the degradation of the lipid matrix and preventing 
the premature release of the encapsulated compound. 
This allows us to conclude that only residual amounts of 
resveratrol will be released until SLNs to reach their tar-
get and that most of the encapsulated compound will be 
released in a controlled and sustained way.
MTT and LDH assays
The potential cytotoxicity of resveratrol-loaded SLNs 
was investigated by MTT and LDH assays on hCMEC/
D3 cells (Fig.  6). For 50  μM resveratrol concentration, 
no statistically significant changes were observed in 
MTT metabolization or LDH release by cells when com-
pared to the positive control (EBM-2 medium), indicat-
ing that up to this concentration SLNs do not affect cell 
viability or membrane integrity. This result showed that 
Fig. 3 Effect of time of storage on zeta potential of resveratrol-
loaded SLNs non-functionalized and functionalized with ApoE. 
Zeta potential after 1 week ( ), 1 month ( ), 3 months ( ) and 
6 months ( ). All data represent the mean ± SD (n = 3). No statisti-
cally significant differences have been found (P > 0.05)
Fig. 4 Effect of time of storage on resveratrol entrapment efficiency 
of non-functionalized SLNs and ApoE-functionalized SLNs. Resveratrol 
entrapment efficiency after 1 week ( ), 1 month ( ), 3 months ( )  
and 6 months ( ). All data represent the mean ± SD (n = 3). No 
statistically significant differences have been found (P > 0.05)
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no relevant cytotoxic effects were observed for the con-
centration used in the permeability studies (50 μM). The 
viability of cells was only affected by about 20 % at con-
centrations higher than 100 μM. These evidences are in 
agreement with the reported effects of this compound, 
since 50 µM resveratrol increased the oxidative phospho-
rylation and mitochondrial biogenesis but concentrations 
higher than 100  μM was described to induce apoptosis 
and mitochondrial dysfunction, resulting in a significant 
decrease in cell viability [30].
Permeability studies
As described before, hCMEC/D3 cell monolayers exhibit 
permeability coefficients well correlated with the in vivo 
permeability data, displaying highly restrictive perme-
ability properties mimicking the in  vivo BBB [32, 33]. 
Hence, hCMEC/D3 cells were cultured in transwell 
devices and permeability studies were carried out to pre-
dict the BBB permeability of resveratrol-loaded SLNs. 
During the experiments, constant TEER values were 
obtained around 150  Ω  cm2, indicating that hCMEC/
D3 monolayer maintained its integrity throughout the 
assay. Moreover, the reported values of Peff of LY tracer 
(1.33 × 10−3 cm/min) were achieved, once again indicat-
ing the proper confluence of cell monolayers. This result 
reveals that SLNs permeability did not occur by tight 
junctions opening or monolayer disruption. In Addi-
tional file  1: Figure S5, it is possible to see the images 
recorded for cell growth on transwell membrane, dur-
ing 7  days after seeding. The permeability profiles and 
respective Papp values after 4  h of assay are shown in 
Fig.  7. It is possible to observe that non-functionalized 
SLNs did not produce a significant change in resveratrol 
permeability through hCMEC/D3 cell monolayers (ca. 
0.55 × 10−5 cm/s). However, a significant increase in res-
veratrol permeability (1.8-fold higher) when encapsulated 
in ApoE-functionalized SLNs is verified comparing to the 
non-functionalized ones. It is also possible to notice that 
there is no significant differences between the maximum 
permeability values reached after 4 h for each functional-
ized SLNs, showing that both strategies applied have the 
same effectiveness in transporting resveratrol through 
the BBB. By this way, it is possible to state that ApoE 
conjugation to nanoparticles really enhances resveratrol-
loaded SLNs permeability through the BBB which might 
lead to an increase of resveratrol brain delivery.
Conclusions
Resveratrol has emerged as a promising natural com-
pound with pleiotropic therapeutic properties and in 
this work we were particularly interested in its neuro-
protective effects. Despite the well-known properties 
of resveratrol, the ability to produce its neuroprotec-
tion effects is largely compromised by its poor pharma-
cokinetic properties. In fact, resveratrol is chemically 
unstable, presents low water solubility and is largely 
metabolized, showing a very low bioavailability [2]. Sev-
eral approaches have been applied trying to overcome 
these limitations [13, 34–36], namely the production 
of nanoparticles capable of protecting it from degra-
dation, thereby increasing topical delivery of resvera-
trol [37–40] or enhancing oral bioavailability [3, 7, 16]. 
However, few studies concern the possibility of resvera-
trol delivery into the brain, being polymeric nanoparti-
cles [41–43] and polymeric nanocapsules containing a 
lipid-dispersed core [44, 45], the most employed nano-
systems. Guo et  al. have used transferrin (Tf )-mod-
ified polyethyleneglycol-polylactic acid (PEG-PLA) 
nanoparticles for resveratrol encapsulation, observ-
ing a significant decrease of brain tumor volume in C6 
glioma-bearing rats [43]. The nanoencapsulation of 
resveratrol in polysorbate 80-coated poly(lactide) nano-
particles also pointed to a promising nanomedical tool 
for PD therapy [42]. This coating with polysorbate 80 
provided the adsorption of ApoE across blood plasma 
onto the nanoparticles surface, promoting the recogni-
tion by LDL receptors in the brain capillary endothelial 
cells [42]. In the present study, we were interested in 
lipid nanoparticles for resveratrol brain delivery, tak-
ing advantage of their favorable characteristics, such 
as their lipophilic nature, their biodegradable and bio-
compatible composition, and their high physical stabil-
ity [18]. To the best of our knowledge, only one study 
in the literature reports the use of such lipid nanopar-
ticles for resveratrol delivery through the BBB, where 
Fig. 5 In vitro resveratrol release profiles from non-functionalized 
SLNs and SLNs functionalized with ApoE performed in SBF, simulating 
the blood stream conditions, at body temperature (37 °C). All data 
represent the mean ± SD (n = 3). * denotes statistically significant 
differences (P < 0.05)
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non-functionalized SLNs significantly increased res-
veratrol concentration in brain when compared to free 
resveratrol [46]. In fact, these lipid nanocarriers have 
shown to be promise as resveratrol delivery systems to 
enhance the therapy of brain disorders. Therefore, in 
the present study we have used lipid nanoparticles with 
covalently attached apolipoprotein E to enhance res-
veratrol brain delivery, applying two strategies recently 
developed [25]. This approach can be supported by 
other studies where apolipoprotein E-enriched nano-
particles can mimic low-density lipoproteins as carriers 
for brain-specific delivery. For instance, nano-low den-
sity lipoproteins have been used as drug delivery vehi-
cles for brain tumors [47]; the brain uptake mechanism 
of ApoE-coated human serum albumin nanoparticles 
was also studied [48]; while ApoE-modified liposomal 
nanoparticles have been reported as promising carri-
ers for gene delivery into the brain [49]. In fact, ApoE 
Receptor 2 appears to be predominantly expressed in 
the brain and binds ApoE with high affinity [50–53]. 
Here, the in  vitro cellular studies performed across 
hCMEC/D3 cells revealed a significant increase of 
Fig. 6 hCMEC/D3 cell viability assessed by MTT assay (a) and cytotoxicity assessed by LDH assay (b) when exposed for 4 h to non-functionalized 
SLN RSV ( ), functionalized SLN-DSPE-ApoE RSV ( ), functionalized SLN-Palmitate-ApoE RSV ( ) and free resveratrol ( ) at different concentra-
tions of resveratrol (from 10 to 100 μM). All values represent the mean ± standard deviation (n = 3). Results were analyzed and compared with 
EBM-2 medium which represents the maximum of cell viability and the minimum of cytotoxicity. * denotes statistically significant differences 
(P < 0.05)
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resveratrol permeability (1.8-fold higher) when encap-
sulated in ApoE-functionalized nanoparticles compared 
to the non-functionalized ones.
In summary, these nanosystems conferred protection 
to this compound and increased its permeability through 
the BBB, which might be a promising strategy for resver-




For the nanoparticles synthesis, the solid lipid cetyl palmi-
tate was provided by Gattefossé (Nanterre, France), poly-
sorbate 80 (Tween 80) was supplied by Merck (Darmstadt, 
Germany) and resveratrol was obtained by Sigma-Aldrich 
(St Louis, MO, USA). In the preparation of pH 7.4 phos-
phate buffer solutions, potassium phosphate monobasic 
was obtained from Sigma-Aldrich and sodium hydroxide 
from Riedel-de Haën (Seelze, Germany). For the nano-
particles functionalization, sodium deoxycholate, avidin, 
NHS-palmitate, EDC and ApoE3 were provided by Sigma-
Aldrich, DSPE-PEG-NH2 was purchased from Avanti Polar 
Lipids (Alabaster, Alabama, USA) and the biotinylation 
reagent [EZ-Link Sulfo-NHS (N-hydroxysuccinimido)-
Biotin] from Thermo Scientific (Waltham, Massachusetts, 
USA). For simulated body fluid preparation, dipotassium 
phosphate was purchased from Sigma-Aldrich; calcium 
chloride, sodium sulfate and tris base were supplied by 
Merck; sodium chloride, magnesium chloride and sodium 
bicarbonate were obtained from Riedel-de Haën; potas-
sium chloride was purchased from Scharlau Chemie S.A. 
(Barcelona, España); and finally, hydrochloric acid was 
supplied by Panreac Química (Barcelona, España). For 
cell culture, phosphate buffered saline (PBS), ascorbic 
acid, dimethylsulfoxide (DMSO), trypsin, human basic 
fibroblast growth factor (bFGF), triton X-100 and hydro-
cortisone were purchased from Sigma-Aldrich. Chemi-
cally defined lipid concentrate, HEPES and PenStrep were 
obtained by Gibco (Carlsbad, CA, USA) and Cultrex Rat 
Collagen I was purchased by R&D Systems (Minneapolis, 
USA). EBM-2 endothelial basal medium was obtained by 
Lonza (Basel, Switzerland) and Fetal Bovine Serum (FBS) 
“Gold” by PAA.
Preparation of nanoparticles
Solid lipid nanoparticles were prepared by the high shear 
homogenization technique followed by sonication, an 
ultrasound method [3, 16, 18]. The lipid phase contain-
ing 500 mg of cetyl palmitate (solid lipid) and 150 mg of 
polysorbate 80 (surfactant) was melted at 70 °C, in order 
to reach the lipid’s melting point. Resveratrol (5 mg) was 
added to the molten lipid and then dispersed in 5  mL 
phosphate buffer (pH 7.4) at the same temperature, by 
high-speed stirring in an Ultra-Turrax T25 (Janke and 
Kunkel IKA-Labortechnik, Staufen, Germany) followed 
by sonication using a Sonics and Materials Vibra-Cell™ 
CV18 (Newtown, CT, USA). Particles in the microm-
eter range were produced by mechanical shearing forces 
produced by the high-speed stirring in the Ultra-Turrax 
(120 s at 12,000 rpm), whereas nanoparticles are obtained 
with the sonication (15 min of 80 % intensity).
Functionalization of nanoparticles with apolipoprotein E
The functionalization of SLNs with ApoE took advantage 
of the strongest known non-covalent interaction between 
avidin and biotin. The process started by the addition of 
the functionally active avidin onto the surface of SLN. 
This addition of avidin was achieved by two different 
strategies: using DSPE-PEG-Avidin or Palmitate-Avidin, 
as described before [25]. Briefly, in the first strategy, SLNs 
were prepared incorporating 10  mg of DSPE-PEG-NH2 
in the lipid phase. The amino terminal group exposed 
on the SLNs surface was subsequently conjugated to a 
carboxyl group of avidin (5  mg/mL) forming a peptide 
bond. In the second strategy, a 15-fold molar excess of 
NHS-palmitate was added to an avidin solution (5  mg/
mL) and incubated at 37 °C for 3 h. SLNs were then pre-
pared as previously described incorporating Palmitate-
Avidin (2 mL) in the lipid phase. The binding of ApoE to 
the SLNs surface was carried out by spontaneous inter-
action between the previously biotinylated ApoE and the 
Fig. 7 a Permeability profile and b Papp of free resveratrol ( ), 
non-functionalized SLNs RSV ( ), SLN-Palmitate-ApoE RSV ( ) and 
SLN-DSPE-ApoE RSV ( ) over 4 h of transport across hCMEC/D3 cell 
monolayer mimicking BBB permeability conditions. All values repre-
sent the mean ± standard deviation (n = 3). Results of resveratrol-
loaded SLNs were analyzed and compared to free-resveratrol.  
* denotes statistically significant differences (P < 0.05)
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covalently attached avidin on the SLNs surface (30 min, 
RT), resulting in two different ApoE-functionalized 
SLNs: SLN-DSPE-ApoE and SLN-Palmitate-ApoE. The 
resulting functionalized formulations were then dialysed 
(10 K MWCO) against PBS (37 °C) to remove the excess 
subtracts and by-products. The confirmation of ApoE 
functionalization was achieved by infra-red spectra anal-
ysis on the lyophilized samples using Fourier Transform 
Infrared Spectroscopy and by fluorimetric assays using a 
fluorescent probe (biotinylated fluorescein) to quantify 
the available biotin-binding sites on the SLNs surface, as 
described elsewhere [25].
Morphology determination
In an attempt to determine and evaluate the morphology 
of the SLNs developed, samples were analyzed by trans-
mission electronic microscopy (TEM). The samples were 
mounted on 300 mesh form var copper grids, stained 
with uranyl acetate, and were examined using a Jeol JEM 
1400 transmission electron microscope (Tokyo). Images 
were digitally recorded using a Gatan SC 1000 ORIUS 
CCD camera (Warrendale, PA, USA), and photomon-
tages were performed using Adobe Photoshop CS soft-
ware (Adobe Systems, San Jose, CA).
Particle size and zeta potential measurements
Particle size analysis was conducted by dynamic 
light scattering (DLS), using a particle size analyzer 
(Brookhaven Instruments, Holtsville, NY, USA). Mean 
hydrodynamic diameter (Z-average), the size distribu-
tion and polydispersity index (PDI) of the nanoparti-
cles in suspension were assessed by this technique. Zeta 
potential was determined by electrophoretic light scat-
tering (ELS) using a ZetaPALS zeta potential analyzer 
(Brookhaven Instruments, Holtsville, NY, USA). Prior 
to the measurements, all samples were diluted (1:200) in 
PBS (pH 7.4) to yield a suitable scattering intensity. The 
average count rate was always between 100 and 500 kcps, 
showing that the dilution applied to the formulations was 
appropriate. The Z-average, PDI and zeta potential were 
obtained by calculating the average of ten runs of three 
independent batches of SLNs.
Resveratrol entrapment efficiency (EE)
To determine the EE of resveratrol, an indirect method 
was used to quantity the amount of free compound 
which still remains in the aqueous phase. SLNs sam-
ples were diluted in phosphate buffer (1:200) and fil-
trated assisted by centrifugation for 10 min at 3300 g in 
Amicon® Ultra-4 Centrifugal Filter Devices (Millipore, 
Billerica, MA, USA) using a Jouan BR4i multifunction 
centrifuge with a KeyWrite-D™ interface (Thermo Elec-
tron, Waltham, MA, USA) with a fixed 23°-angle rotor. 
Nanoparticles were then retained in the filter while the 
total amount of non-encapsulated resveratrol were pre-
sent in the supernatant and quantified using a V-660 
spectrophotometer (Jasco, Easton, MD, USA) at 305 nm. 
The EE was then calculated:
EE =
Total amount of resveratrol −Nonencapsulated resveratrol
Total amount of resveratrol
× 100
In vitro resveratrol release studies
The in  vitro resveratrol release studies were performed 
using Float-A-Lyzer G2 dialysis devices (Spectrum® Lab-
oratories, Inc) with a biotech grade cellulose ester dialysis 
membrane (with a nominal molecular weight cut off of 
3.5–5 kD). Our aim was to mimic the bloodstream condi-
tions to simulate the release of resveratrol from nanopar-
ticles during its traffic until it reaches their target (BBB). 
For this purpose, it was used a simulated body fluid (SBF) 
developed by Kokubo and his team that has inorganic 
ion concentrations nearly equal to those of human blood 
plasma and is buffered at pH 7.4 [28, 29]. Diluted samples 
(1:12, v/v) were incubated for 28 h in SBF at body tem-
perature (37 °C) while being stirred at 100 rpm. At regu-
lar intervals, aliquots were collected and replaced with 
the same volume of fresh medium of SBF to maintain 
the sink conditions. The amount of resveratrol released 
was quantified using a Synergy™ HT Multi-mode Micro-
plate Reader (BioTek Instruments Inc, Winooski, VT, 
USA). The release studies were conducted in quadrupli-
cate and the cumulative percentage of the released com-
pound was determined by calculating the average of all 
the experiments.
Cell studies
Immortalized human cerebral microvascular endothe-
lial cells (hCMEC/D3) were obtained under license from 
Institut National de la Santé et de la Recherche Médicale 
(INSERM, Paris, France). This cell line shows a similar 
morphology to primary cultures of brain endothelial cells, 
representing one such model of the human BBB that can 
be easily grown and is very useful to cellular and molecular 
studies, being an important research tool for the charac-
terization of the interactions between drugs or formula-
tions and brain endothelial cells [32, 33]. hCMEC/D3 cells 
between passage number 26 and 34 were used in all stud-
ies, since they maintain stable growth and endothelial 
marker characteristics, at least until passage 35 [33]. Cells 
were seeded in a concentration of 2.5 × 104 cells/cm2 and 
grown at 37  °C, in an atmosphere of 5 % CO2 in EBM-2 
medium supplemented with 1 % Pen-Strep, 2 % FBS gold, 
1 % chemically defined lipid concentrate, 5 μg/ml ascorbic 
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acid, 1.4 μM hydrocortisone, 10 mM HEPES and 1 ng/ml 
bFGF. 0.1 mg/mL rat collagen type I was used to pre-coat 
all flasks, 1 h at 37 °C. Cell culture medium was changed 
every 2–3  days. Cell pictures were recorded using an 
inverted microscope (Motic AE2000 TRI coupled with a 
camera Moticam 5 MP; Spain).
MTT and LDH assays
To access the cell viability after SLNs exposition, it was per-
formed the MTT assay, since the level of MTT cleavage in 
formazan by cells is directly proportional to the number 
of live and viable (metabolic active) cells [54]. LDH assays 
were also conducted in order to evaluate the cell death lev-
els and more specifically the potential of SLNs in causing 
damage in cell membrane. This technique allows the lactate 
dehydrogenase (LDH) quantification, an enzyme that is 
released from cells to the surrounding cell culture superna-
tant when there is damage or rupture of the cell cytoplas-
mic membranes. Cells were seeded in 96-well plates (104 
cells per well) pre-coated with type I collagen. After 20 h of 
incubation at 37 °C and 5 % CO2, different concentrations 
of free resveratrol and resveratrol-loaded SLNs (function-
alized and non-functionalized) were incubated with the 
cells for 4 h. Positive and negative controls were also used 
to ensure the reliability of this technique. EBM-2 medium 
represents the maximum of cell viability and the minimum 
of cytotoxicity, while triton-X 100 represents the minimum 
of cell viability and the maximum of cytotoxicity. After the 
exposition time, the medium of each well was separated 
from the cells and stored for further use in LDH assay and 
cells were treated with 0.5 mg/ml of MTT for 4 h, at 37 °C 
and 5  % CO2. DMSO was added to each well to dissolve 
MTT formazan and plates were incubated for more 15 min 
at 37 °C, in the dark. The medium resulting from the incu-
bation of samples with cells were collected and centrifuged 
(250 g for 10 min, at room temperature) and the superna-
tant separated from the deposited cells in each well. With 
this centrifugation, it is removed any wastes and cellular 
debris and also SLNs. The LDH release into culture super-
natants was detected by adding catalyst and dye solutions 
of LDH cytotoxicity detection kit (Takara Bio Inc, Shiga, 
Japan), after an incubation of 20 min at room temperature 
in the dark. Absorbance was read at 490 and 690 nm using 
a Synergy™ HT Multi-mode Microplate Reader (BioTek 
Instruments Inc, Winooski, VT, USA). Cell viability and 
cytotoxicity were expressed as a percentage derived from 
the ratio of the absorbance of treated cells compared to 
the control obtained by incubating cells only with culture 
medium (EBM-2) at the same conditions.
Permeability studies
For permeability experiments, hCMEC/D3 cells were 
seeded on transwell filters pre-coated with type I 
collagen (polyester 6 well, pore size 0.4 µm and a diam-
eter of 4.67 cm2) in a density of 2 × 105 cells per insert. 
Cell medium was changed 3  days after seeding and the 
permeability assay was performed 7  days after seed-
ing. In order to ensure the integrity of hCMEC/D3 
monolayer, the transendothelial electrical resistance 
(TEER) was monitored with an epithelial voltohmmeter 
(EVOM) from World Precision Instruments (Sarasota, 
FL, USA). In addition, the quality of the monolayers 
was tested by measuring the effective permeability (Peff) 
of lucifer yellow (LY), a highly hydrophilic test com-
pound, comparing the values obtained with the previ-
ously reported ones [55]. The Peff of LY was found to be 
1.32  ±  0.07  ×  10−3  cm/min (when 20  µM of LY were 
applied on the apical donor compartment) which is con-
sistent with the 1.33 × 10−3 cm/min found in literature, 
meaning the suitable monolayer confluence for the assays 
performed with resveratrol-loaded SLNs [55, 56].
For the permeability studies, free resveratrol (50  μM) 
and resveratrol-loaded SLNs (functionalized and non-
functionalized with ApoE) were incubated in the apical 
donor compartment for 4 h at 37 °C and 5 % CO2 atmos-
phere. The concentration of resveratrol in the receptor 
compartment was quantified every 30 min during 4 h, by 
fluorescence analysis (330/374 nm) and the apparent per-
meability coefficients (Papp) of SLNs were calculated by 
the equation Papp(cm/ s) = QA.C .t, where Q represents the 
total amount of permeated resveratrol (μg) in each time 
point, A is the surface area of the membrane filter (cm2), 
C is the initial resveratrol concentration (μg/cm3) and t is 
the experiment time (s).
Statistical analysis
The statistical analysis was performed using SPSS soft-
ware (v 22.0; IBM, Armonk, NY, USA). The values 
obtained represent the average of at least three experi-
ments and data were expressed as mean  ±  SD. Data 
were analyzed using one-way analysis of variance (one-
way ANOVA), followed by Bonferroni and Tukey post 
hoc tests. A P value of 0.05 was considered statistically 
significant.
Additional file
Additional file 1: Table S1. Characterization of Resveratrol-loaded 
SLNs: SLN placebo and SLN-Resveratrol (2, 5, 10 and 15 mg of resveratrol). 
Figure S1. Effect of time of storage on particle size of RSV loaded SLNs 
with different amounts of RSV. Figure S2. Effect of time of storage on 
zeta potential of RSV loaded SLNs with different amounts of RSV. Figure 
S3. Effect of time of storage on entrapment efficiency of RSV loaded SLNs 
with different amounts ofRSV. Figure S4. In vitro RSV release profiles from 
RSV loaded SLNs with different amounts of RSV performed in SBF, simulat-
ing the blood stream conditions, at body temperature (37 ºC). Figure 
S5. Images of hCMEC/D3 cells on transwell devices during the 7 days of 
growing.
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